4 results
A complete list of objectives is presented in Section 2.1 Objectives of the Study Protocol. In summary, the primary objective of this study is to demonstrate a superior LDL-C lowering effect of PF 04950615 150 mg administered by the SC route Q2wks…
To determine the clinical efficacy and toxicity of ABT-869 in combination with paclitaxel in the first-line treatment of subjects with metastatic breast cancer.
A complete list of the study objectives is presented in the Objectives section of the protocol. In summary, the primary objective of this study is to demonstrate a superior LDL-C lowering effect of PF-04950615 150 mg administered by the SC route…
The aim of this prospective single-arm phase II study is to evaluate the efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFRTKI (osimertinib or lazertinib), for patients with EGFR-mutant advanced NSCLC,…